Do genetic variants in SLC28A3 and UGT1A6 predict anthracycline-induced cardiotoxicity in children?
A prediction model combining genetic variants in SLC28A3 and UGT1A6 with clinical risk factors may help identify pediatric patients at high risk for anthracycline-induced cardiotoxicity.
. We validated genetic variants in two genes predictive of ACT in an independent cohort. A prediction model combining replicated genetic variants as well as clinical risk factors might be able to identify high- and low-risk patients who could benefit from alternative treatment options.
Visscher et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: